The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Open accessAbstract
Purpose: To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 (HER2) testing in breast cancer guideline. Methods: Based on the signals approach, an Expert Panel reviewed published literature and research survey results on the observed frequency of less common in situ hybridization (ISH) patterns to update the recommendations. Recommendations: Two recommendations addressed via correspondence in 2015 are included. First, immunohistochemistry (IHC) 2+ is defined as invasive breast cancer with weak to moderate complete membrane staining observed in > 10% of tumor cells. Second, if the initial HER2 test result in a core needle biopsy specimen of a primary breast cancer is negative, a new HER2 test may (not “must”) be ordered on the excision specimen based on specific clinical criteria. The HER2 testing algorithm for breast cancer is updated to address the recommended work-up for less common clinical scenarios (approximately 5% of cases) observed when using a dual-probe ISH assay. These scenarios are described as ISH group 2 ( HER2/chromosome enumeration probe 17 [CEP17] ratio ≥ 2.0; average HER2 copy number < 4.0 signals per cell), ISH group 3 ( HER2/CEP17 ratio < 2.0; average HER2 copy number ≥ 6.0 signals per cell), and ISH group 4 ( HER2/CEP17 ratio < 2.0; average HER2 copy number ≥ 4.0 and < 6.0 signals per cell). The diagnostic approach includes more rigorous interpretation criteria for ISH and requires concomitant IHC review for dual-probe ISH groups 2 to 4 to arrive at the most accurate HER2 status designation (positive or negative) based on combined interpretation of the ISH and IHC assays. The Expert Panel recommends that laboratories using single-probe ISH assays include concomitant IHC review as part of the interpretation of all single-probe ISH assay results. Find additional information at www.asco.org/breast-cancer-guidelines .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Self-citationHammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Self-citationWolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030
Self-citationWolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-18-asocco · Cited by 1,816
Self-citationWolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2014) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2013-0953-sa · Cited by 1,762
Self-citationHow Quickly Do Systematic Reviews Go Out of Date? A Survival Analysis
Shojania, K. G., Sampson, M., Ansari, M. T., Ji, J., Doucette, S., & Moher, D. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-4-200708210-00179 · Cited by 838
Van Poznak, C., Somerfield, M. R., Bast, R. C., Cristofanilli, M., Goetz, M. P., Gonzalez-Angulo, A. M., Hicks, D. G., Hill, E. G., Liu, M. C., Lucas, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.1459 · Cited by 404
Giordano, S. H., Temin, S., Kirshner, J. J., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Esteva, F. J., Gonzalez-Angulo, A. M., Krop, I., Levinson, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0948 · Cited by 343
Krop, I., Ismaila, N., Andre, F., Bast, R. C., Barlow, W., Collyar, D. E., Hammond, M. E., Kuderer, N. M., Liu, M. C., Mennel, R. G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.0472 · Cited by 315
Self-citationHanna, W. M., Rüschoff, J., Bilous, M., Coudry, R. A., Dowsett, M., Osamura, R. Y., Penault-Llorca, F., van de Vijver, M., & Viale, G. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.103 · Cited by 281
Self-citationUpdated UK Recommendations for HER2 assessment in breast cancer
Rakha, E. A., Pinder, S. E., Bartlett, J. M. S., Ibrahim, M., Starczynski, J., Carder, P. J., Provenzano, E., Hanby, A., Hales, S., Lee, A. H. S., et al. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202571 · Cited by 255
Self-citationPartridge, A. H., Rumble, R. B., Carey, L. A., Come, S. E., Davidson, N. E., Di Leo, A., Gralow, J., Hortobagyi, G. N., Moy, B., Yee, D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.7479 · Cited by 240
Marchiò, C., Lambros, M. B., Gugliotta, P., Di Cantogno, L. V., Botta, C., Pasini, B., Tan, D. S., Mackay, A., Fenwick, K., Tamber, N., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2574 · Cited by 202
Ma, C. X., Bose, R., Gao, F., Freedman, R. A., Telli, M. L., Kimmick, G., Winer, E., Naughton, M., Goetz, M. P., Russell, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0900 · Cited by 193
Ramakrishna, N., Temin, S., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Esteva, F. J., Giordano, S. H., Gonzalez-Angulo, A. M., Kirshner, J. J., Krop, I., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0955 · Cited by 191
Yeh, I., Martin, M. A., Robetorye, R. S., Bolla, A. R., McCaskill, C., Shah, R., Gorre, M. E., Mohammed, M. S., & Gunn, S. R. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.78 · Cited by 144
Press, M. F., Sauter, G., Buyse, M. E., Fourmanoir, H., Quinaux, E., Tsao-Wei, D. D., EIERMANN, W., Robert, N. J., Pieńkowski, T., Crown, J. P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6693 · Cited by 142
Self-citationDenduluri, N., Somerfield, M. R., Eisen, A. F., Holloway, J. N., Hurria, A., King, T. A., Lyman, G. H., Partridge, A. H., Telli, M. L., Trudeau, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.0182 · Cited by 134
Self-citationTse, C. H., Hwang, H. C., Goldstein, L. C., Kandalaft, P. L., Wiley, J. C., Kussick, S. J., & Gown, A. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0107 · Cited by 119
Middleton, L. P., Price, K. M., Puig, P., Heydon, L. J., Tarco, E., Sneige, N., Barr, K., & Deavers, M. T. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.5.775 · Cited by 108
Henry, N. L., Somerfield, M. R., Abramson, V. G., Allison, K. H., Anders, C. K., Chingos, D. T., Hurria, A., Openshaw, T. H., & Krop, I. E. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.8609 · Cited by 98
Self-citationShah, M. V., Wiktor, A. E., Meyer, R. G., Tenner, K., Ballman, K. V., Green, S. J., Sukov, W. R., Ketterling, R. P., Perez, E. A., & Jenkins, R. B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.8983 · Cited by 85
Self-citationPress, M. F., Villalobos, I. E., Santiago, A., Guzman, R., Cervantes, M., Gasparyan, A., Campeau, A., Ma, Y., Tsao-Wei, D. D., & Groshen, S. G. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0009-oa · Cited by 69
Self-citationLim, T. H., Lim, A. S. T., Thike, A. A., Tien, S. L., & Tan, P. H. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0108-oa · Cited by 52
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Allison, K. H., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., Hanna, W. M., Jenkins, R. B., Mangu, P. B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7559 · Cited by 32
Self-citationSneige, N., Hess, K. R., Multani, A. S., Gong, Y., & Ibrahim, N. K. (2016) · Cancer · doi:10.1002/cncr.30460 · Cited by 31
Hanna, W. M., Barnes, P. J., Chang, M. C., Gilks, C. B., Magliocco, A. M., Rees, H., Quenneville, L., Robertson, S. J., Sengupta, S., & Nofech‐Mozes, S. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.6092 · Cited by 17
Self-citation
Research works printed but not linked: 20
- Fehrenbacher L, Cecchini RS, Geyer CE, et al: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → (A) weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC). Presented at San Antonio Breast Cancer Symposium, December 5-9, 2017 San Antonio, TX · doi:10.1158/1538-7445.sabcs17-gs1-02
- 10.1200/JCO.2016.70.5319 · doi:10.1200/jco.2016.70.5319
- 10.1038/modpathol.2016.175 · doi:10.1038/modpathol.2016.175
- 10.1200/JCO.2014.59.7211 · doi:10.1200/jco.2014.59.7211
- Bethune GC, 2015, Histopathology, 67, 880, 10.1111/his.12723 · doi:10.1111/his.12723
- 10.1093/ajcp/aqw224 · doi:10.1093/ajcp/aqw224
- 10.1111/his.12147 · doi:10.1111/his.12147
- 10.1093/annonc/mdp234 · DOI
- 10.1309/9EYM6VE58F2YCD9F · doi:10.1309/9eym6ve58f2ycd9f
- 10.1007/s10549-009-0539-2 · doi:10.1007/s10549-009-0539-2
- 10.1007/s12253-014-9852-0 · doi:10.1007/s12253-014-9852-0
- 10.1093/ajcp/aqv018 · doi:10.1093/ajcp/aqv018
- 10.1016/j.clbc.2017.03.012 · doi:10.1016/j.clbc.2017.03.012
- 10.1309/AJCP3Q9WFOQTKUVV · doi:10.1309/ajcp3q9wfoqtkuvv
- 10.1371/journal.pone.0140652 · doi:10.1371/journal.pone.0140652
- Xu Y, 2016, Zhonghua Bing Li Xue Za Zhi, 45, 545
- 10.1007/s00428-015-1871-z · doi:10.1007/s00428-015-1871-z
- Singh K, 2016, Breast Cancer Res Treat, 157, 405, 10.1007/s10549-016-3824-x · doi:10.1007/s10549-016-3824-x
- 10.1007/s10549-016-3717-z · doi:10.1007/s10549-016-3717-z
- 10.1309/AJCPE5NCHWPSMR5D · doi:10.1309/ajcpe5nchwpsmr5d
Cited by
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., Tsurutani, J., Ueno, N. T., Prat, A., Chae, Y. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203690 · Cited by 2,664
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Metadata
- Authors
- Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., Jenkins, R. B., Press, M. F., Spears, P. A., Vance, G. H., Viale, G., McShane, L. M., & Dowsett, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-07-10
- Volume
- 36
- Issue
- 20
- Pages
- 2105-2122
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2806209829
- Cited by
- 2,435
- References
- 27
- FWCI
- 53.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.